trending Market Intelligence /marketintelligence/en/news-insights/trending/-lwyIwkJTQSV7l4sCN4LFQ2 content esgSubNav
In This List

ASCO conference: Pfizer lung cancer drug improves survival in phase 3 trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: Pfizer lung cancer drug improves survival in phase 3 trial

Pfizer Inc. said its investigational compound dacomitinib showed a seven-month improvement in overall survival of lung cancer patients compared to AstraZeneca PLC's Iressa.

Patients who received dacomitinib as a first-line, or initial, treatment had a median overall survival of 34.1 months, compared to 26.8 months for those who received Iressa, also called gefitinib.

The results are from a phase 3 study, called Archer 1050, which enrolled patients with locally advanced or metastatic non-small cell lung cancer with mutations related to epidermal growth factor receptor — a protein associated with cell division.

Additionally, survival rate in the dacomitinib group was 56.2% at 30 months, compared to 46.3% in the gefitinib group.

Adverse events observed were consistent previous dacomitinib trial results, with the most common complications being diarrhea, nail changes, rash/dermatitis acneiform and mouth sores.

The U.S. Food and Drug Administration is expected to make a decision on Pfizer's marketing application for dacomitinib in September.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on site and an additional 3,350 abstracts to be published online.